Education Center

Advancements in the Delivery of Biologics for the Treatment of Diabetes

Funding for this newsletter series was provided by AstraZeneca

 

Diabetes medication administration often forces patients into uncomfortable situations. Those with complicated treatment or with a fear of needles might hesitate to adhere to their suggested regimen, placing themselves at risk. Over the years, several mechanisms have evolved to help make insulin delivery, and so, betting patient adherence.

This fifth eNewsletter in the series, entitled Advancements in the Delivery of Biologics for the Treatment of Diabetes was written by James Ruggles, PhD, and James Meehan, MSc. It covers the history of insulin delivery methods starting from 1922 and through present day.

Click here to read the supplement

About the Authors:

James Ruggles, PhD
AstraZeneca
Wilmington, DE, USA

James Meehan, MSc
AstraZeneca
Macclesfield, Cheshire, UK

Next Article: